All In Biotech

Drug Trial Radar · NCT00055874

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase

Last checked: Nov 19, 2026Latest source record: May 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,551 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,551

Actual

Start

Jun 2002

Primary completion

Mar 31, 2012

Study completion Mar 31, 2017

Sponsor

Lead sponsor
Heidelberg UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, imatinib mesylate may stop the growth of cancer cells by blocking the enzymes needed for cancer cell growth. Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known which treatment regimen is most effective in treating chronic phase chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying imatinib mesylate with or without interferon alfa or cytarabine to see how well it works compared with interferon alfa followed by donor stem cell transplant in treating patients with newly diagnosed chronic phase chronic myelogenous leukemia.

Conditions

  • Leukemia

Interventions

  • recombinant interferon alfaBiological

  • cytarabineDrug

  • hydroxyureaDrug

  • imatinib mesylateDrug

  • allogeneic bone marrow transplantationProcedure

  • autologous bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival
  2. Risk group-dependent survival
  3. Progression-free survival
  4. Hematologic, cytogenetic, and molecular response rates

Locations

66 sites in 2 countries. Site status is shown where the registry gives one.

  • Krankenhaus / Klinikum Krefeld

    Aachen, Germany

  • Kreiskrankenhaus Aurich

    Aurich, Germany

  • Kreiskrankenhaus

    Bad Hersfeld, Germany

  • St. Hedwig Krankenhaus

    Berlin, Germany

  • Haematologisch-Onkologische Schwerpunktpraxis

    Berlin, Germany

  • Schwerpunktpraxis fuer Haematologie und Internistische Onkologie

    Berlin, Germany

  • Gemeinschaftspraxis fuer Haematologie und Internistische Onkologie

    Berlin, Germany

  • Onkologische Schwerpunktpraxis Bielefeld

    Bielefeld, Germany

  • Augustinum

    Bonn, Germany

  • Hamatologische Sprechstunde

    Brandenburg, Germany

  • Praxis Dres. F.& G. Doering

    Bremen, Germany

  • Staedtisches Kliniken Delmenhorst

    Delmenhorst, Germany

  • Universitaetsklinikum Essen

    Essen, Germany

  • Evangelisches Krankenhaus Essen Werden

    Essen, Germany

  • Klinikum der J.W. Goethe Universitaet

    Frankfurt, Germany

  • Internistische Praxisgemeinschaft

    Germering, Germany

  • DR Herbert - Nieper Krankenhaus Goslar

    Goslar, Germany

  • Universitaetsklinikum Goettingen

    Göttingen, Germany

  • St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH

    Hagen, Germany

  • Asklepios Klinik St. Georg

    Hamburg, Germany

  • University Medical Center Hamburg - Eppendorf

    Hamburg, Germany

  • Evangelische Krankenhaus Hamm

    Hamm, Germany

  • Medizinische Universitaetsklinik und Poliklinik

    Heidelberg, Germany

  • Universitatsklinikum Heidelberg

    Heidelberg, Germany

  • Ruprecht - Karls - Universitaet Heidelberg

    Heidelberg, Germany

  • Medical University Hospital Homburg

    Homburg, Germany

  • Universitaetsklinikum des Saarlandes

    Homburg, Germany

  • Westpfalz-Klinikum GmbH

    Kaiserslautern, Germany

  • Staedtisches Klinikum Karlsruhe gGmbH

    Karlsruhe, Germany

  • St. Vincentius - Kliniken

    Karlsruhe, Germany

  • Klinikum Kempten Oberallgaeu

    Kempten, Germany

  • University Hospital Schleswig-Holstein - Kiel Campus

    Kiel, Germany

  • Klinikum Krefeld GmbH

    Krefeld, Germany

  • Internistisches Fachaerzte Zentrum Langen

    Langen, Germany

  • Caritas - Krakenhaus Lebach

    Lebach, Germany

  • Onkologische Schwerpunktpraxis - Leer

    Leer, Germany

  • Klinikum Lippe - Lemgo

    Lemgo, Germany

  • Klinikum der Stadt Ludwigshafen am Rhein

    Ludwigshafen am Rhein, Germany

  • III Medizinische Klinik Mannheim

    Mannheim, Germany

  • Hospital Maria-Hilf II

    Mönchengladbach, Germany

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.